AI Generated Image
Thyroid medication recalled nationwide over potential superpotency risk
Fox Business • • business
Key Points:
- Vitruvias Therapeutics is voluntarily recalling Lot 504950 of Thyroid Tablets, USP 30 mg nationwide due to potential "superpotent" tablets that may cause hyperthyroidism.
- The recall affects 3,655 units released, with 1,955 units sold, distributed between January 31, 2025, and September 30, 2025, and carries an expiration date of September 30, 2026.
- Excessive thyroid hormone from these tablets poses significant health risks, especially to elderly patients, pregnant women, and infants, including cardiac problems, premature delivery, and developmental issues.
- Patients taking the affected medication are advised not to stop use without consulting a healthcare provider, and Vitruvias is notifying wholesalers to halt distribution and arrange destruction of the product.
- The recall is conducted with FDA oversight, and consumers with questions or adverse event reports are encouraged to contact Vitruvias Therapeutics or their healthcare provider.
